The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.80
Bid: 9.35
Ask: 9.75
Change: 0.20 (2.08%)
Spread: 0.40 (4.278%)
Open: 10.20
High: 10.40
Low: 9.80
Prev. Close: 9.60
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Jun 2014 13:41

RNS Number : 1742K
e-Therapeutics plc
20 June 2014
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

E-Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

19 June 2014

6. Date on which issuer notified:

20 June 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

37%,36%,35%,34%,33% & 32%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary 1p Shares

GB00B2823H99

102,724,060

102,724,060

84,524,060

32.01%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

84,524,060

32.01%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Invesco Fund Managers Limited - 81,738,356

Invesco Asset Management Limited - 2,785,704

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Philippa Sadler

15. Contact telephone number:

01491 417 000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAAKEALELEFF
Date   Source Headline
15th Feb 20223:27 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
20th Jan 202210:58 amRNSNew Corporate Website
18th Jan 20224:41 pmRNSHolding(s) in Company
7th Jan 20227:00 amRNSDirector Dealing and Issue of Equity
22nd Nov 20217:00 amRNSSenior Management Update
26th Oct 20211:55 pmRNSDirector Dealing
26th Oct 20217:01 amRNSInterim results for six months ended 31 July 2021
26th Oct 20217:00 amRNSRNAi Platform Characterisation Results
20th Oct 20217:00 amRNSInvestor Presentation
11th Oct 20217:05 amRNSPatent Filing Applications
11th Oct 20217:00 amRNSNotice of Interim Results
24th Sep 20217:00 amRNSCommencement of trading on the OTCQX Best Market
2nd Sep 20214:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSTotal Voting Rights
6th Jul 20217:00 amRNSDirector Dealing and Issue of Equity
2nd Jul 20217:00 amRNSFurther milestone in Galapagos collaboration
30th Jun 20217:00 amRNSTotal Voting Rights
21st Jun 20213:13 pmRNSHolding(s) in Company
21st Jun 20217:00 amRNSHolding(s) in Company
18th Jun 202112:52 pmRNSHolding(s) in Company
17th Jun 20213:44 pmRNSHolding(s) in Company
16th Jun 20211:27 pmRNSResult of AGM
2nd Jun 20217:00 amRNSSenior Management Appointment and Options Grant
21st May 20217:00 amRNSNotice of AGM and Posting of Annual Report
14th May 20217:00 amRNSResults of conditional Fundraise to raise £22.5m
13th May 20214:50 pmRNSRetail Offer
13th May 20214:45 pmRNSProposed Fundraise in excess of £20 million
13th May 20217:00 amRNSFinal Results for the Year Ended 31 January 2021
6th May 20217:00 amRNSNotification of Full Year Results Date
23rd Apr 20217:00 amRNSETX to receive two payments from Galapagos
29th Mar 20217:00 amRNSAppointment of Chief Financial Officer
1st Mar 20217:00 amRNSBoard Changes
1st Mar 20217:00 amRNSChange of Adviser
25th Feb 20213:29 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSe-therapeutics to present at Shares Evening
10th Feb 20214:35 pmRNSHolding(s) in Company
1st Feb 20217:00 amRNSRNA Therapeutics Platform
28th Jan 20214:40 pmRNSSecond Price Monitoring Extn
28th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 202111:24 amRNSHolding(s) in Company
4th Jan 20214:31 pmRNSDirector/PDMR Shareholding
18th Dec 20205:44 pmRNSHolding(s) in Company
16th Dec 202012:38 pmRNSHolding(s) in Company
8th Dec 202011:07 amRNSCOVID-19 Project Update
21st Oct 20209:06 amRNSIssue of Equity
12th Oct 20203:15 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.